Glucagon-like peptide 1 (GLP-1) is a promising candidate for the treatment of type II diabetes. However, the short in vivo half-life of GLP-1 has made peptide-based treatments challenging. Gene therapy aimed at achieving continuous GLP-1 expression presents one way to circumvent the rapid turnover of GLP-1. We have created a GLP-1 minigene that can direct the secretion of active GLP-1 (amino acids 7-37). Plasmid and adenoviral expression vectors encoding the 31-amino-acid peptide linked to leader sequences required for secretion of GLP-1 yielded sustained levels of active GLP-1 that were significantly greater than endogenous levels. Systemic administration of expression vectors to animals using two diabetic rodent models, db/db mice and Zucker Diabetic Fatty (ZDF) rats, yielded elevated GLP-1 levels that lowered both the fasting and random-fed hyperglycemia present in these animals. Because the insulinotropic actions of GLP-1 are glucose dependent, no evidence of hypoglycemia was observed. Improved glucose homeostasis was demonstrated by improvements in %HbA1c (glycated hemoglobin) and in glucose tolerance tests. GLP-1-treated animals had higher circulating insulin levels and increased insulin immunostaining of pancreatic sections. GLP-1-treated ZDF rats showed diminished food intake and, in the first few weeks following vector administration, a diminished weight gain. These results demonstrate the feasibility of gene therapy for type II diabetes using GLP-1 expression vectors.
Introduction
Type II diabetes is characterized by two principal defects: insulin resistance in peripheral tissues and defective insulin secretion from beta cells. 1 These two pathologies lead to a progressive beta-cell failure that results in a loss of beta-cell mass and the need for hypoglycemic agents used alone, or in combination with insulin replacement therapy, to control blood glucose. Although many drugs are initially adequate as monotherapies, their effectiveness wanes over time and polypharmacy is often required. This is most likely due to the polygenic and progressive nature of type II diabetes and that current treatments do not arrest the deterioration in beta-cell function.
Glucagon-like peptide-1 (GLP-1) is a 30 amino-acid peptide that is secreted from the L-cells of the intestine in response to meal ingestion.
2,3 GLP-1 has a variety of effects related to nutrient digestion and acts primarily in the pancreas, intestine, and brain as a prandial agent that dampens blood glucose excursions. In the pancreas, GLP-1 has been shown to stimulate glucose-induced insulin secretion as well as insulin production. 4, 5 GLP-1 has also been shown to preserve beta-cell function and to stimulate beta-cell replication and neogenesis. [6] [7] [8] In the intestine and brain, GLP-1 acts as an ileal brake by slowing the rate of gastric emptying, promoting feelings of satiety and diminishing food intake. [9] [10] [11] [12] [13] [14] There are also reports of GLP-1 acting to decrease glucagon secretion, promote glucose uptake in skeletal muscle, and stimulate hepatic glycogen synthesis. [15] [16] [17] [18] [19] [20] The combined properties of GLP-1 action make it an attractive candidate for treatment of type II diabetes but its actions on the beta-cell render it unique for potentially changing the course of disease. In addition, treatments such as insulin secretagogues or parenteral administration of insulin are associated with significant risks of hypoglycemia. Because GLP-1 increases insulin secretion only in the presence of elevated glucose, the risks of hypoglycemia are low. As a consequence, several GLP-1 analogs are being evaluated pre-clinically and clinically as a treatment for type II diabetes. 21 However, use and development of GLP-1 as a therapeutic agent is hampered by its short half-life owing to degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase and clearance by the kidney. 22, 23 One approach to extend serum half-life utilizes analogs of GLP-1 that maintain potent blood glucose lowering effects but are peptidase resistant. Exendin-4 (EX4) is a GLP-1 homolog found in the venom of the Gila monster. It has a high affinity for the GLP-1 receptor and is a poor substrate for DPP-IV and neutral endopeptidase, which results in a greatly extended half-life. 24 Another approach is based on leveraging the long half-life of serum albumin. This has been accomplished either by direct conjugation of GLP-1 analogs to albumin 25 or by attachment of an albumin-binding fatty acid. 26 A recombinant albumin-GLP-1 fusion protein is also under investigation. 27 However, even these stabilized forms require daily injection for full efficacy. Patient compliance is a key component of diabetes management and once or twice daily injection may present a significant hurdle for adoption of any therapeutic.
Ectopic expression of GLP-1 in vivo represents an alternate strategy for peptide delivery. Cells transduced with a GLP-1 expression vector could serve as a depot for continuous production of GLP-1 and because the insulinotropic actions of GLP-1 are glucose dependent, constitutively elevated GLP-1 should not cause hypoglycemia. Previously published studies on plasmidmediated GLP-1 gene delivery used a form of GLP-1 that was not engineered for secretion and achieved only minimal elevations in circulating GLP-1 with modest and transient effects on blood glucose in a rat model of type II diabetes or mouse model of diet-induced obesity. 28, 29 Here, we describe the construction and analysis of novel GLP-1 plasmid and adenoviral expression vectors that generate significantly elevated circulating peptide levels in vivo. We demonstrate efficacy of these vectors in two well-studied rodent models of type II diabetes, db/db mice and Zucker Diabetic Fatty (ZDF) rats. These results establish proof of concept for a gene therapy of type II diabetes using ectopic expression of GLP-1.
Results
GLP-1 is encoded by the preproglucagon gene. Differential post-translational processing of preproglucagon in the intestine and pancreas results in the secretion of GLP-1 and glucagon, respectively. This processing is due to the actions of distinct prohormone convertases that are differentially expressed in these two tissues. GLP-1 is generated in the L-cells of the gut by the action of the prohormone convertase PC3, while glucagon is generated in pancreatic alpha-cells by PC2. 30 These proteases are restricted to a subset of endocrine and neuroendocrine cell types and thus are not practical for generating GLP-1 from preproglucagon expressed in non-endocrine tissues. Furthermore, use of a preproglucagon transgene could result in the unpredictable production of glucagon, its C-terminally extended forms, or other processed peptides with unclear function. We therefore constructed a GLP-1 minigene encoding only the 31 amino acids present in GLP-1 . Because the active form of GLP-1 (7-37 or 7-36 amide) is rapidly cleaved to an inactive form (9-37 or 9-36 amide) by DPP-IV, 22 the alanine at position 8 was mutated to glycine to render the peptide DPP-IV resistant and thus prolong its circulating halflife. 31 To facilitate its production and secretion in ectopic, non-endocrine tissues, it was necessary to attach a signal peptide to GLP-1 that would target the peptide to the constitutive secretory pathway and allow post-translational processing of the hybrid peptide by signal peptidase, a ubiquitous enzyme. The signal peptide from secreted alkaline phosphatase (SEAP) was linked to the GLP-1-coding region (Figure 1a) . We also tested another means of processing the hybrid peptide by fusing GLP-1 to a furin protease recognition sequence that was then linked to the leader sequence from EX4 ( Figure 1a ). Using this strategy, a panel of GLP-1 expression vectors containing a variety of leader sequences was generated, including signal peptides from SEAP and clusterin, and leaders from EX4, glucose-dependent insulinotropic peptide (GIP), and helodermin (Hel).
Expression vectors containing these hybrid mini-genes were transfected into 293 cells and the cell supernatants were assayed for the presence of GLP-1 3 days following transfection. The use of radioimmunoassays specific for the N-and C-termini of GLP-1 confirmed the presence of significant amounts of processed GLP-1 in the cell supernatants. The data from a representative experiment using the N-terminal radioimmunoassay (RIA) is shown in Figure 1b and demonstrates that constructs containing a furin-cleavable leader sequence (solid bars) produce significantly more GLP-1 than constructs containing just a signal peptide (striped bars).
In order to confirm that the constructs are capable of producing elevated circulating GLP-1 levels in vivo, plasmid DNA was administered to BALB/c mice via high-volume tail vein injection. The next day following vector administration, high levels of GLP-1 could be detected in the plasma of injected mice (Figure 1c ). The RIA is specific for the C-terminus of GLP-1 (7-37) and thus measures GLP-1 (total), the combined amount of active-and DPP-IV-cleaved GLP-1. As endogenous GLP-1 is predominantly in the 7-36 amidated form, there was no detectable GLP-1 in the control vehicle-injected mice. Circulating GLP-1 levels in the mice injected with a GLP-1 expression vector were several orders of magnitude greater than the reported endogenous levels of 10-20 pM. Consistent with the transient transfection experiments, constructs containing a furin-cleavable leader yielded significantly higher GLP-1 levels than a construct employing just a signal peptide. The construct containing the modified exendin leader and the Gly8 mutation, termed EX4GLP1Gly8, yielded the highest GLP-1 levels and was chosen for further experiments. Additional experiments (see below) with the N-terminal RIA confirmed correct processing of GLP-1.
We next wished to determine whether GLP-1 expressed in vivo would be effective in improving glycemic control in a model of type II diabetes. Diabetic db/db mice are deficient in leptin signaling and are obese and hyperphagic. They are also severely insulin resistant and start developing hyperglycemia by 4 weeks of age. GLP-1 linked to the EX4 leader sequence was cloned into an expression vector harboring the CMV enhancer linked to the ubiquitin promoter and intron (CUbi). The CUbi vector is capable of directing expression for more than 1 month in the liver. 32 Third-generation adenoviral vectors provide a simple and efficient tool for achieving sustained, high levels of gene expression. Therefore, an adenoviral vector containing the CUbi-EX4GLP1Gly8 transcription cassette was constructed for use in experiments in diabetic animal models. The vector backbone contains deletions in the E1, E3B, and E4 regions but retains E4 ORF6. 33, 34 The vector was administered to the tail vein of db/db mice at a dose of 1 Â 10 11 viral particles per mouse. Control mice received adenovirus devoid of a transgene (empty vector (EV)). The blood glucose of Ad2/GLP-1-treated db/db mice declined to a level equivalent to that of lean mice within 1 day following vector administration ( Figure 2a) . Glucose levels rose out of the euglycemic range over the next week but even at 6 weeks post-vector administration, glucose levels were GLP-1 gene therapy for type II diabetes GB Parsons et al still significantly (Po0.001) below the level of the Ad2/EVtreated mice. GLP-1 vector administration to non-diabetic lean mice resulted in a small but statistically significant (P ¼ 0.02) decline in blood glucose without evidence of hypoglycemia. The improved blood glucose was also reflected in a lower %HbA1c (glycated hemoglobin) for the treated mice (Table 1) , 42 days post-treatment.
GLP-1 levels were measured using an RIA specific for the N-terminus of GLP-1 (7-37) and thus detected active GLP-1 and not the inactive DPP-IV cleavage product. Plasma levels of active GLP-1Gly8 in db/db mice were 41 nM 6 weeks after vector administration ( Figure  2b ). Despite an equivalent dose of Ad2/GLP-1, GLP-1 levels were not as high in treated lean animals. In addition, elevated GLP-1 levels were not sustained in Ad2/GLP-1-treated lean mice. Several of the animals showed a reduction to undetectable levels by 6 weeks post-vector administration. The reason for this is unclear but could be owing to an immune response to the Gly8 version of GLP-1. Endogenous GLP-1 levels in control animals were in the normal range.
Diabetic db/db mice are severely insulin resistant and thus have greatly elevated circulating insulin levels. On the C57BLKS/J (black Kaliss) background, db/db mice experience a progressive beta-cell failure that eventually results in a large reduction in circulating insulin levels and a dramatic rise in blood glucose. db/db mice treated with Ad2/GLP-1 experienced only a small, statistically insignificant, reduction in plasma insulin levels, whereas the Ad2/EV-treated db/db mice showed a greater than 60% decline in circulating insulin (Table 1) . Thus, GLP-1 treatment resulted in a delay of the appearance of insulin deficiency in this strain. In addition, a glucose tolerance test performed at 2 weeks post-vector administration also showed that the GLP-1-treated db/db mice had improved glucose homeostasis (Figure 2c ). Although the two groups had similar peaks of blood glucose excursion, the GLP-1-treated animals had significantly lower glucose levels at 120 and 180 min time points (Po0.02, Po0.01, respectively). At the last time point, the glucose levels of the treated db/db mice were not significantly different from the lean controls (P ¼ 0.14). 
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We investigated whether the maintenance of circulating insulin levels was reflected in a preservation of betacell mass. In a separate study, db/db mice were injected with Ad2/CUbiEX4GLP-1Gly8 or Ad2/EV. At 28 days after vector administration, pancreatic sections were immunostained for insulin. Representative images are shown in Figure 3a -c. Lean mice showed small, densely staining, islets (Figure 3a) , whereas db/db mice had larger lightly staining islets (Figure 3b and c) . GLP-1-treated db/db mice tended to have larger islets ( Figure  3c ) than control db/db mice. This increased islet size resulted in a significant (Po1 Â 10
À4
) increase in the overall fraction of the pancreas staining positive for insulin (Figure 3d) .
We evaluated GLP-1 gene therapy in another model of type II diabetes, the ZDF rat. Similar to db/db mice, these obese animals carry a mutation in the leptin receptor, are hyperphagic, insulin resistant, and experience a progressive decline in beta-cell function that leads to severe hyperglycemia. Eight-week-old male ZDF rats received a tail vein injection of Ad2/ CUbiEX4GLP-1Gly8 at a dose of 1 Â 10 12 viral particles. The hyperglycemia was corrected in these animals within a few days of vector administration; the blood glucose levels of the Ad2/GLP-1-treated ZDF rats declined to the level of the lean controls, whereas the blood glucose of the Ad2/EV-treated ZDF rats continued to increase ( Figure 4a ). As was seen in lean mice, there was a small but statistically significant (Po1 Â 10
) decrease in the blood glucose of the Ad2/ GLP-1-treated lean rats, but no hypoglycemia was observed. The differences in blood glucose in the lean groups were significant only until 1-week post-vector administration. The Ad2/GLP-1-treated ZDF rats remained euglycemic for the next 3 weeks and then glucose levels rose slowly over the final 3 weeks of the study. At the end of the study, most of the Ad2/GLP-1-treated animals were modestly hyperglycemic (Po0.04) with only one of the animals showing blood glucose greater than 300 mg/dl. ZDF rats typically develop fasting hyperglycemia by 11 weeks of age. At 5 weeks post-vector administration (13 weeks of age), the GLP-1-treated ZDF rats still had not developed fasting hyperglycemia, whereas the empty vector-treated animals had fasting glucose levels greater than 200 mg/dl ( Table 2 ). The improved blood glucose of the Ad2/GLP-1-treated animals is also reflected in a lower %HbA1c, o6% for Ad2/GLP-1-treated animals versus 412% for Ad2/EV-treated animals ( Table 2 ). Both of the lean groups had a %HbA1c of o5%.
Circulating levels of active GLP-1Gly8 (7-37) were B1 nM and persisted with only a slight drop (P ¼ 0.05) during the entire 6 weeks of the study (Figure 4b ).
In contrast to what was observed with lean mice, lean control rats treated with Ad2/GLP-1 maintained elevated plasma GLP-1 levels.
Progressive beta-cell failure is a key feature of the ZDF rat model. As expected, plasma insulin declines in these animals as diabetes progresses 35 ( Figure 4c ). Interestingly, insulin levels were not statistically different in the Ad2/GLP-1-treated group compared to the Ad2/EV group in the first week following vector administration. However, by the end of the study, the Ad2/GLP-1-treated group had significantly higher (P ¼ 0.01) plasma insulin levels than the Ad2/EV group. As was observed 
in db/db mice, Ad2/GLP-1 treatment appeared to significantly delay the onset of beta-cell failure.
As GLP-1 has been shown to delay gastric emptying and promote feelings of satiety, we wanted to determine whether Ad2/GLP-1 treatment would result in a decrease in food intake and consequently impact body weight in the ZDF rats. Ad2/GLP-1-treated ZDF rats consumed less food throughout the 6 weeks of the study (Figure 5a ) and, early on, showed a diminished body weight gain (Figure 5b) . However, by three weeks postvector administration, the Ad2/EV control group had stopped gaining weight and by the end of the study the Ad2/GLP-1-treated ZDF rats actually showed an increased body weight gain when compared with the Ad2/EV-treated controls (Po0.04). This differential weight gain is expected 35 and is probably due to the progressive decline in beta-cell function and insulin levels that result in poor glucose utilization and glucosuria in Ad2/EV-treated animals. The GLP-1-treated animals did not show as large a decline in circulating insulin and were able to continue gaining weight. Thus, during the first half of the study, the Ad2/ GLP-1-treated group showed a diminished weight gain when compared with the Ad2/EV group, most likely 
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GB Parsons et al because food intake was reduced. By the second half of the study, severe insulin deficiency in the Ad2/EVtreated group resulted in a diminished weight gain due to poor energy utilization in the diabetic state. In fact, when compared to the growth rate of lean controls (Figure 5c ), the Ad2/GLP-1-treated ZDF rats showed a normal change in body weight. Similar to the ZDF rats, the lean rats treated with Ad2/ GLP-1 showed decreased food intake throughout the course of the study and a small decrease in body weight during the first week following vector administration (Figure 5c ). Subsequent to this initial weight loss, the two lean groups showed a similar rate of weight gain. In contrast to the obese animals, the two lean groups showed no change in circulating insulin levels and the Ad2/GLP-1-treated animals showed significantly diminished weight gain, despite a similar rate of increase during the last 5 weeks of the study. Thus, the weight loss that occurred during the first week of the study was maintained over the subsequent weeks.
Discussion
We have created a GLP-1 minigene that can direct the secretion of active GLP-1 . Transient transfection experiments demonstrated that the most efficient production of GLP-1 (7-37) was achieved by linking the GLP-1-coding region to a leader sequence containing a signal peptide as well as a furin recognition site. A mutation of the alanine at position 8 to glycine was included to render the peptide resistant to DPP-IV cleavage. Administration of GLP-1 expression vectors to animals either as naked plasmid DNA or as an adenoviral vector demonstrated that GLP-1 gene delivery can yield sustained levels of circulating active GLP-1 (7-37) that are several orders of magnitude greater than endogenous levels and are significantly greater than the circulating levels that have been reported to be efficacious in patients in clinical trials of GLP-1 and EX4 peptide therapy. For reasons that are not clear, GLP-1 levels were lower and not sustained in treated lean mice compared to db/db mice. This could be owing to different transduction efficiency of the db/db liver or to generation of an immune response to GLP-1 carrying the Gly8 mutation. As this phenomenon was not observed in lean Zucker rats, it was not pursued further. This demonstrates that production of therapeutic amounts of GLP-1 via gene therapy is feasible in these rodent models of diabetes. A previously published attempt at GLP-1 gene therapy 29 achieved only a partial, transient effect on blood glucose. This limited effect is probably due to poor secretion of GLP-1 from the transduced cells, because the transgene did not include a signal peptide.
As the insulinotropic actions of GLP-1 are glucose dependent, no evidence of hypoglycemia was found, even in lean non-diabetic animals. Both db/db mice and ZDF rats showed dramatic improvements in glucose homeostasis as a result of GLP-1 vector administration, which was evident in fed and fasting blood glucose measurements, %HbA1c, and glucose tolerance tests. These animal models experience rapid beta-cell failure that results in severe insulin deficiency. Constitutive GLP-1 expression resulted in a significant delay of this decline in beta-cell function and enabled the maintenance of effective insulin levels. The exact mechanism of this delay is not known as GLP-1 has been demonstrated to have a number of effects that serve to improve insulin production and secretion. This includes stimulation of 
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insulin transcription, translation, and glucose-dependent secretion. 4, 5 Furthermore, GLP-1 has been reported to have positive effects on beta-cell mass through stimulation of beta-cell replication, beta-cell neogenesis, and inhibition of apoptosis. 7, 8, 36 In addition to these direct actions of GLP-1, correction of hyperglycemia is predicted to diminish beta-cell death owing to glucotoxicity. 37 Consistent with other published reports, 36 we observed a greater than twofold increase in the beta-cell mass of GLP-1-treated db/db mice compared to control empty vector-treated db/db mice. Multiple kinetic studies will be required to determine whether this increase is owing to changes in rates of beta-cell replication, neogenesis, or inhibition of apoptosis. Alternatively, increases in insulin transcription or translation may facilitate greater detection of beta-cells.
Whereas the insulinotropic properties of GLP-1 treatment are well studied, the effects of GLP-1 on insulin sensitivity are less clear. Shortly after vector administration to ZDF rats, GLP-1 treatment resulted in a normalization of blood glucose levels as well as a lowering (although not significantly) of circulating insulin levels. This implies an improvement in insulin sensitivity. However, GLP-1 treatment has also been shown to blunt postprandial glucose excursions by delaying gastric emptying, and a blunted glucose excursion would result in a decreased insulin requirement. In fact, studies in humans have shown that a delay in gastric emptying results in a smaller peak of insulin secretion following meal ingestion. 38 In addition, GLP-1 has been proposed to directly stimulate glucose uptake in muscle and fat by acting through a putative, yet uncharacterized, GLP-1 receptor. 39 However, as GLP-1 and EX4 do not have glucose lowering effects in GLP-1 receptor knockout mice, it would seem that this mechanism plays a minor role in the action of GLP-1. 40 Furthermore, since hyperglycemia itself can cause insulin resistance, 41 correction of blood glucose levels should have positive effects on insulin sensitivity. In previous studies with EX4, improvements in insulin sensitivity were observed. 42, 43 Hyperinsulinemic/euglycemic clamp studies will be required to definitively demonstrate whether GLP-1 gene therapy has an effect on insulin sensitivity.
GLP-1 gene therapy does not halt the rapid beta-cell failure present in these diabetic rodent models but does result in a significant delay in its progression. The decline in beta-cell function is much more severe than that found in patients with type II diabetes. The causes of the beta-cell defect in these animals are not entirely understood 44 but it is clear that they are dependent on the genetic background. For example, the db mutation in C57/B6 mice results in severe insulin resistance and obesity but without the beta-cell failure that is observed on the C57BLKS/J background. 45 As a result, the C57/B6 mice do not experience a decline in insulin, only develop mild hyperglycemia, and continue gaining weight throughout their life.
GLP-1 gene therapy caused a decrease in food intake. This effect is most pronounced in the first few days following vector administration, when food intake was lowered to approximately 10% of that prior to treatment (data not shown). Food intake eventually rose to about 80% of pre-administration levels. The cause of the acute effects are not known but may be related to the nausea that is a common side effect reported in clinical trials of GLP-1 and EX4 peptide therapy. Although the nausea was usually reported as mild and transient, it was severe enough in some cases to cause patient withdrawal from the trial. GLP-1 gene therapy caused a reduction in body weight during the first week following treatment, a period that coincided with the greatest effect on food intake. It is not clear whether the more modest effect on food intake was sufficient to impact body weight as the control obese animals become so insulin deficient that they ceased to gain weight. Our results are consistent with the idea that GLP-1 treatment, through its insulinotropic actions, restored adequate energy utilization, resulting in continued weight gain. GLP-1 vector administration to lean Zucker rats also had significant effects on both food intake and body weight. Lean Ad2/ GLP-1-treated rats showed diminished food intake that resulted in a reduced weight gain. In the lean animals, GLP-1 treatment had minimal impact on plasma insulin levels. Weight loss occurred during the first week following vector administration and this difference in body weight was maintained for the remainder of the study. Treatment with NN2211, a long-acting derivative of GLP-1, has previously been observed to result in longterm weight loss in rats. 46 It is also possible that GLP-1 may have effects on body weight that extend beyond its anorectic effects, as was observed for oxyntomodulin, a peptide that is also produced from preproglucagon and is thought to act through the GLP-1 receptor. 47 These studies show that a single administration of a GLP-1 expression vector can yield significant, prolonged improvements to glucose homeostasis in animals with severe diabetes. Such a treatment presents an alternative to continuous infusion needed for GLP-1 peptide therapy Po0.04.
or to the daily injections required for stabilized forms of GLP-1 or EX4. Patient compliance is a major component of successful diabetes management and it has long been understood that the need for injection presents a significant obstacle to the adoption of a therapy. Therefore, it is reasonable to assume that this route of administration will represent a hurdle to the adoption of GLP-1 peptide therapy. There may also be physiologic advantages to GLP-1 gene therapy compared to a peptide therapy. It has been shown that continuous infusion of GLP-1 has a greater impact than bolus injection on first-phase insulin secretion. 48 As the constitutively elevated levels present with GLP-1 gene therapy are analogous to a continuous infusion, there may be additional benefits to GLP-1 gene therapy beyond improved patient compliance.
Systemic administration of adenoviral and plasmid vectors results primarily in transduction of the liver. However, administration of gene therapy vectors need not be limited to delivery to the liver. A broad range of tissues could be used for production of GLP-1. Whereas adenoviral vectors provide a simple and efficient tool for achieving high levels of gene expression, alternative vector systems are currently being explored for delivery of a GLP-1 transgene.
Materials and methods

Plasmid vector constructions
A nucleotide sequence encoding the signal peptide from human-secreted alkaline phosphatase (SEAP) linked to GLY-8-modified GLP-1 (GLP-1Gly8) was generated by ligation of overlapping synthetic oligonucleotides. The codon-optimized sequence was cloned into the EcoRI and KpnI sites of the expression vector pCI (Promega, Madison, WI, USA) to create pCISEAPGLP-1Gly8. To create additional expression vectors, pCISEAPGLP1Gly8 was cut with EcoRI and BtrI, which removes the SEAP signal peptide and a portion of the GLP-1 sequence. The sequences were replaced with fragments generated by overlapping oligonucleotides containing the signal peptide for clusterin (amino acids or the leaders for proexendin-4 (amino acids 1-42), pro-helodermin (amino acids 1-41), or pro-glucose-dependent insulinotropic polypeptide (GIP) (amino acids 1-46) and the missing portion of GLP-1. The sequence from proexendin-4 that was used to create pCIEX4GLP-1Gly8 is shown in Figure 1a . Sequences for additional constructs spanning EcoRI to BtrI are as follows: clusterin GAATTCGCCGCCACCATGATGAAGACTCTGCTGCT GTTTGTGGGGCTGCTGCTGACCTGGGAGAGTGGGC AGGTCCTGGGGCACGGCGAGGGCACCTTCACCAG CGAC; pro-helodermin GAATTCCGC-CCACCATGAA GAGCATCCTGTGGCTGTGTGTGTTTGGCCTGCTGAT TGCCACCCTGTTCCCTGTGAGCTGGCAGATGGCCA TCAAGAGCAGACTGTCCTCTGAGGACTCTGAGACA GACCAGAGACTGAAGCGCATCAAGCGCCACGGCG AGGGCACCTTCACCAGCGAC; pro-GIP GAATTCCGC CC-ACCATGGTGGCCACCAAGACCTTTGCCCTGCTG CTCCTGAGCCTCTTCCTGGCTGTGGGACTGGGCGAG AAGAAGGAAGGCCACTTCAGCGCCCTGCCCAGCCT GCCAGTGGGCAGCCATGCCAAGGTGAGCTCCCCAC AGAAGCGCATCAAGCGCCACGGCGAGGGCACCTTC ACCAGCGAC. 
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The vector pGZCUbiEX4GLP-1Gly8 was constructed by excising the EX4GLP-1Gly8 gene from pCIEX4GLP-1Gly8 as an ScaI-NotI fragment and ligating into pGZCUbi digested with NotI and blunted on the 5 0 end.
Recombinant adenovirus
Adenovirus expressing EX4GLP-1Gly8 was generated by excising the GLP-1 expression cassette from pGZCUbiEX4GLP-1Gly8 as an SphI (blunt)/MfeI fragment and ligating into the EcoRV and MfeI sites of pSV2-ICeu1. 49 The GLP-1 cassette was then excised by ICeu1 digestion and ligated into ICeu1 restricted D1.6 E3/orf6 to create pAd2\CUbiEX4GLP-1Gly8D1.6E3/orf6. Virus was generated by transfection of 293 cells with an SnaBI partial restriction of pAd2\CUbiEX4GLP-1Gly8D1.6E3/ orf6. 49 Viruses were propagated and purified and the titers of the virus were determined, all as previously described. 34 
Transient transfection
Transfections were carried out using the calcium phosphate method (MBS Transfection, Stratagene, La Jolla, CA, USA) in 293 cells in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Transfection efficiency was normalized using a co-transfected, secreted alkaline phosphatase (SEAP) reporter construct. Cells (1 Â 10 6 ) were transfected with mixtures containing 5 mg of GLP-1 vector and 0.5 mg of SEAP vector. GLP-1 concentrations in cell supernatants were determined using a radioimmunoassay (RIA, Linco Research, St Charles, MO, USA) specific for the amino terminus of GLP-1. SEAP activity was measured using the ALP-50 alkaline phosphatase kit purchased from Sigma Diagnostics (St Louis, MO, USA).
Animal experiments
All animal experiments were carried out in accordance with protocols and guidelines established by the Genzyme IACUC. GLP-1 expression constructs were tested in 6-to 8-week-old male BALB/c mice (Jackson Labs, Bar Harbor, ME, USA). Mice were housed at four animals per group. High volume tail vein injections were performed as described. 50 Plasma samples were obtained from retro-orbital bleeds of isoflorane-anesthetized animals 24 h after plasmid administration.
Female db/db mice, 7-8 weeks of age, were obtained from Jackson Laboratories and housed in groups of five. Mice received a tail vein injection (150 ml) containing 1 Â 10 11 viral particles diluted in phosphate-buffered saline (PBS). In the study examining insulin staining of pancreatic sections, 7-to 8-week-old female db/db mice were housed in groups of four. Mice received a tail vein injection (150 ml) containing 1.2 Â 10 11 viral particles diluted in PBS.
Male ZDF rats, 6 weeks of age, were obtained from Charles River Labs (Wilmington, MA, USA), housed in groups of two, and fed a diet of Purina 5008. The rats received a tail vein injection (1 ml) containing 1 Â 10 12 viral particles diluted in PBS.
Glucose tolerance tests were performed on mice following an overnight fast. The animals were injected i.p. with 0.2 ml of a 200 mg/ml glucose solution. Subsequent glucose measurements were performed using a One Touch glucose meter (LifeScan, Milpitas, CA, USA).
Plasma analyses
Blood glucose values were determined in the morning from tail vein blood using a One Touch glucose meter (LifeScan). %HbA1c was determined on 10 ml of whole blood using an A1cNow test kit (Metrika, Sunnyvale, CA, USA). For the expression study, plasma GLP-1Gly8 (total) levels were determined in BALB/c mice using an RIA with an antibody specific for the C-terminus of GLP-1 (Peninsula Labs, Belmont, CA, USA). In experiments examining efficacy in diabetic animals, GLP-1Gly8 (active) levels were quantitated using an RIA containing an antibody specific for the amino terminus of GLP-1 (Linco Research). The RIA assay was not sensitive enough to accurately determine endogenous GLP-1 levels. In control animals, GLP-1 was measured using a GLP-1 ELISA (Linco Research). Unlike the RIA, this assay did not detect the GLP-1Gly8 mutation. Plasma insulin levels were determined by RIA (Linco Research). Significance of observed differences between groups was tested by single factor analysis of variance (ANOVA).
Insulin immunohistochemistry
Upon harvest, pancreata were fixed for 24 h in zinc formalin (EMS, Hartfield, PA, USA) and embedded in paraffin for histological studies. The slides were deparaffinized by immersion in three baths of Hemo-De (Scientific Safety Solvents, Keller, TX, USA) and rehydrated in two baths of 100% ethanol, two baths of 95% ethanol, one bath of 70% ethanol, one bath of 50% ethanol, and three baths of distilled water. Endogenous peroxidase activity was destroyed by 30 min room temperature incubation in 3% hydrogen peroxide. Slides were incubated with 5% goat serum (Jackson ImmunoResearch, West Grove, PA, USA) for 10 min, washed in PBS and then incubated overnight at 41C with a polyclonal guinea-pig anti-insulin antibody (Dako, Carpinteria, CA, USA) diluted 1:1500 in PBS+1% bovine serum albumin (BSA). After several PBS washes, slides were incubated for 1 h at 371C with a peroxidase-labeled goat anti-guinea pig IgG (Jackson ImmunoResearch, West Grove, PA, USA) diluted 1:500 in PBS. Slides were washed once in PBS and once in 50 mM Tris-HCl pH 7.5. Signal was detected using DAKO liquid DAB SubstrateChromogen System (Dako, Carpinteria, CA, USA). Reaction was stopped by washing in water. Slides were then counterstained with Blue Mayer's hematoxylin.
Quantitation of islet area
Three sections of whole pancreas from each animal were imaged following insulin immunohistochemistry. The relative islet area was determined by quantification of the cross-sectional area occupied by beta-cells and the total pancreatic cross-sectional area with Metamorph (Universal Imaging, Dowington, PA, USA) image analysis software.
